Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Graphite Bio, Inc. - Common Stock (NQ:GRPH)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Graphite Bio, Inc. - Common Stock

< Previous 1 2 Next >
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
From Graphite Bio, Inc.
Via Business Wire
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EngageSmart, Inc. (NYSE – ESMT), WaveDancer, Inc. (Nasdaq – WAVD), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EngageSmart, Inc. (NYSE – ESMT), WaveDancer, Inc. (Nasdaq – WAVD), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR),
From Brodsky & Smith LLC
Via GlobeNewswire
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Departure of Chief Financial Officer
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Jefferies Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio, Inc. (NASDAQ:GRPH) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/26/2022 -- An investigation on behalf of current long-term investors in shares of Graphite Bio, Inc. (NASDAQ:GRPH) was announced over potential breaches of fiduciary... 
Via SBWire
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Upcoming Investor Conferences
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program
From Graphite Bio, Inc.
Via Business Wire
NASDAQ:GRPH Shareholder Notice: Investigation over Possible Securities Laws Violations by Graphite Bio, Inc.
San Diego, CA -- (SBWIRE) -- 04/13/2022 -- Graphite Bio, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.